Published in Neuropharmacology on December 01, 2004
Cav1.4 IT mouse as model for vision impairment in human congenital stationary night blindness type 2. Channels (Austin) (2013) 1.21
Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. Neuropharmacology (2011) 1.03
Salt craving: the psychobiology of pathogenic sodium intake. Physiol Behav (2008) 1.02
New paradigms for treatment-resistant depression. Ann N Y Acad Sci (2013) 0.94
The clinical implications of mouse models of enhanced anxiety. Future Neurol (2011) 0.89
Postpartum depression and role of serum trace elements. Iran J Psychiatry (2010) 0.85
GPR39 (zinc receptor) knockout mice exhibit depression-like behavior and CREB/BDNF down-regulation in the hippocampus. Int J Neuropsychopharmacol (2014) 0.84
Neural substrates for the distinct effects of presynaptic group III metabotropic glutamate receptors on extinction of contextual fear conditioning in mice. Neuropharmacology (2012) 0.84
Cell-type-specific tuning of Cav1.3 Ca(2+)-channels by a C-terminal automodulatory domain. Front Cell Neurosci (2015) 0.81
Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. BMC Complement Altern Med (2011) 0.77
Zinc in the Glutamatergic Theory of Depression. Curr Neuropharmacol (2015) 0.77
Modulation of antidepressant-like activity of magnesium by serotonergic system. J Neural Transm (Vienna) (2007) 0.76
The severity of depressive symptoms vs. serum Mg and Zn levels in postmenopausal women. Biol Trace Elem Res (2013) 0.76
Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway. Psychopharmacology (Berl) (2014) 0.75
Role of Cellular Magnesium in Human Diseases. Austin J Nutr Food Sci (2014) 0.75
Reduced Anxiety-Like Behavior and Altered Hippocampal Morphology in Female p75NTR(exon IV-/-) Mice. Front Behav Neurosci (2016) 0.75
The interactive effects of ketamine and magnesium upon depressive-like pathology. Neuropsychiatr Dis Treat (2016) 0.75
Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. J Clin Invest (2004) 1.69
Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med (2004) 1.48
Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol (2008) 1.40
The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression. J Neurosci (2010) 1.29
Impaired extinction of learned fear in rats selectively bred for high anxiety--evidence of altered neuronal processing in prefrontal-amygdala pathways. Eur J Neurosci (2008) 1.26
Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des (2009) 1.04
A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol (2005) 1.03
Behavioral and neurobiological effects of deep brain stimulation in a mouse model of high anxiety- and depression-like behavior. Neuropsychopharmacology (2013) 0.95
New paradigms for treatment-resistant depression. Ann N Y Acad Sci (2013) 0.94
Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression-like behaviour: effects of chronic paroxetine treatment. J Neurochem (2005) 0.94
Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol (2003) 0.89
Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics (2007) 0.87
Airjet and FG-7142-induced Fos expression differs in rats selectively bred for high and low anxiety-related behavior. Neuropharmacology (2006) 0.87
Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior. Amino Acids (2011) 0.87
St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial. J Psychiatr Res (2010) 0.86
Conditional CRF receptor 1 knockout mice show altered neuronal activation pattern to mild anxiogenic challenge. Psychopharmacology (Berl) (2006) 0.84
Neural substrates for the distinct effects of presynaptic group III metabotropic glutamate receptors on extinction of contextual fear conditioning in mice. Neuropharmacology (2012) 0.84
Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement. Psychoneuroendocrinology (2005) 0.84
The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res (2006) 0.84
A mouse model of high trait anxiety shows reduced heart rate variability that can be reversed by anxiolytic drug treatment. Int J Neuropsychopharmacol (2011) 0.82
Effect of neuropeptide Y Y2 receptor deletion on emotional stress-induced neuronal activation in mice. Synapse (2009) 0.81
Increased levels of conditioned fear and avoidance behavior coincide with changes in phosphorylation of the protein kinase B (AKT) within the amygdala in a mouse model of extremes in trait anxiety. Neurobiol Learn Mem (2012) 0.81
Role of L-type Ca2+ channel isoforms in the extinction of conditioned fear. Learn Mem (2008) 0.81
Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.80
Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review. Prim Care Companion J Clin Psychiatry (2010) 0.80
Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. J Psychiatr Res (2002) 0.79
Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. Psychoneuroendocrinology (2005) 0.77
Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol (2011) 0.77
Sub-chronic treatment with an extract of Hypericum perforatum (St John's wort) significantly reduces cortisol and corticosterone in the rat brain. Eur Neuropsychopharmacol (2004) 0.77
Changes in the sleep electroencephalogram (EEG) during male to female transgender therapy. Psychoneuroendocrinology (2011) 0.77
St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) (2002) 0.77
Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers. Psychopharmacology (Berl) (2005) 0.77
Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology (2004) 0.76
Alpha-helical CRH exerts CRH agonistic effects on sleep-endocrine activity in humans. Neuropsychobiology (2005) 0.76
Pharmacophore modeling, virtual screening, and in vitro testing reveal haloperidol, eprazinone, and fenbutrazate as neurokinin receptors ligands. J Chem Inf Model (2014) 0.76
Dr. David F. Horrobin. Prostaglandins Leukot Essent Fatty Acids (2003) 0.75
Stereoselective and region-specific induction of immediate early gene expression in rat parietal cortex by blockade of neurokinin 1 receptors. J Psychopharmacol (2005) 0.75